NPM1 and acute myeloid leukemia: In phase Ib, no responses were observed in the patients treated at 200 mg of Ziftomenib; at the recommended dose for phase II (600 mg), the rate of CR + CRi was 12.5% (2/16) in the KMT2A-rearranged and 35% (7/20) in the NPM1-mutant AML patients; the ORR in the KMT2A-rearranged AML patients was 17% and 45% in the NPM1-mutant AML patients; the median OS was 6.0 and 5.6 months, respectively, in the KMT2A-rearranged and NPM1-mutant AMLs [123].